Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

149
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
149
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

750
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
750
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

790
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
790
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.1K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.1K
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology01:29

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

1.2K
Gastroesophageal Reflux Disease (GERD) involves the recurrent backflow of the stomach or duodenal contents into the esophagus, leading to troublesome symptoms and potential esophageal mucosal damage. Although GERD is often referred to as a disease, it is more accurately described as a syndrome, as it encompasses a range of symptoms and complications rather than a singular pathological entity, impacting a large number of individuals as the most prevalent upper gastrointestinal problem. Roughly...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAR1 Controls Macrophage Scavenging and Lipid-Buffering Programs in Metabolic Tissues.

European journal of immunology·2026
Same author

Protocol for the injection of adenoviruses into brown adipose tissue in mice.

STAR protocols·2026
Same author

The hypothalamus as a therapeutic target: Towards novel approaches for managing antipsychotic-induced weight gain.

Reviews in endocrine & metabolic disorders·2025
Same author

Increased levels of syndecan-3 are associated with childhood obesity.

iScience·2025
Same author

Hepatic Olfr734 Deficiency Worsens Hepatic Glucose Metabolism and Induces MASLD in Mice.

Nutrients·2025
Same author

Hepatic lipid metabolism is altered in Ubiad1<sup>+/-</sup> mice of both sexes.

Scientific reports·2025

Related Experiment Video

Updated: Jan 3, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K

Ghrelin and liver disease.

Mar Quiñones1,2, Johan Fernø3, Omar Al-Massadi4,5,6

  • 1Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain.

Reviews in Endocrine & Metabolic Disorders
|November 24, 2019
PubMed
Summary

Modulating the ghrelin system shows promise for treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review explores ghrelin pathways regulating liver metabolism, inflammation, and fibrosis, suggesting a potential therapeutic strategy.

Keywords:
GhrelinHepatic fibrosisLipid metabolismNAFLDNASHObesity

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

16.2K

Related Experiment Videos

Last Updated: Jan 3, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

16.2K

Area of Science:

  • Hepatology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions linked to obesity and metabolic syndrome.
  • Current pharmacological treatments for NAFLD and NASH are limited, highlighting the need for novel therapeutic approaches.
  • Understanding the molecular mechanisms underlying these diseases is crucial for developing effective interventions.

Purpose of the Study:

  • To review the current knowledge on ghrelin system modulation for liver disease treatment.
  • To explore the role of ghrelin and its intracellular pathways in regulating hepatic lipid metabolism, inflammation, and fibrosis.
  • To discuss novel mechanisms, including autophagy and circadian rhythms, influenced by ghrelin in liver disease.

Main Methods:

  • Literature review compiling recent findings on ghrelin system modulation.
  • Analysis of preclinical animal models investigating ghrelin's effects on liver pathophysiology.
  • Synthesis of information on ghrelin's intracellular signaling pathways relevant to liver health.

Main Results:

  • Ghrelin system modulation has emerged as a promising therapeutic strategy in preclinical models of liver disease.
  • Ghrelin influences key pathways involved in hepatic lipid metabolism, inflammation, and fibrosis.
  • Novel roles for ghrelin in regulating autophagy and circadian rhythms in the context of liver disease have been identified.

Conclusions:

  • The ghrelin system presents a compelling therapeutic target for managing NAFLD and NASH.
  • Further research into ghrelin's multifaceted roles could unlock new treatment avenues for liver diseases.
  • Targeting the ghrelin system offers a potential strategy to address the growing burden of metabolic liver disease.